美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效观察

The Curative Effect of Metoprolol Combined With Trimetazidine Treatment of Coronary Heart Disease Patients With Heart Failure Sibutramine

目的探究美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效。方法根据用药方案不同将75例冠心病心力衰竭患者分为联合组(40例)和对照组(35例),分别给予美托洛尔联合曲美他嗪和常规药物治疗,比较两组临床治疗效果。结果联合组治疗后血压、心率、左室射血分数等指标改善均优对照组,治疗总有效率(95.0%)高于对照组(80.0%),比较差异有统计学意义(P<0.05)。结论在常规药物治疗基础上加用美托洛尔和曲美他嗪,有助于改善冠心病心力衰竭患者临床症状和心功能,且安全性较高。

Objective To explore clinical efficacy of metoprolol combined with trimetazidine treatment of coronary heart disease and heart failure trimetazidine. Methods According to different regimens, 75 patients with coronary heart disease and heart failure were randomly divided into the treatment group（40 cases） and control group（35 cases）, were treated with metoprolol combined with trimetazidine sibutramine and conventional drug treatment, compare clinical therapeutic effect of two groups. Results Combined group after treatment of blood pressure, heart rate, left ventricular ejection fraction and other indicators were superior to the control group, the total efficiency of treatment（95.0%） was higher than the control group（80.0%）, the difference was statistically significant（P〈 0.05）. Conclusion Combined with on the basis of conventional drug treatment sibutramine metoprolol and trimetazidine, help to improve the clinical symptoms of coronary heart disease patients with heart failure and heart function, and high safety.